{"protocolSection":{"identificationModule":{"nctId":"NCT02796664","orgStudyIdInfo":{"id":"KGC2016-26"},"organization":{"fullName":"Asan Medical Center","class":"OTHER"},"briefTitle":"Preventive Effects of Ginseng Against Atherosclerosis","officialTitle":"Preventive Effects of Ginseng Against Atherosclerosis and Subsequent Ischemic Stroke: A Randomized Controlled Trial","acronym":"PEGASUS"},"statusModule":{"statusVerifiedDate":"2021-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-06-23","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2018-07-04","type":"ACTUAL"},"completionDateStruct":{"date":"2018-07-04","type":"ACTUAL"},"studyFirstSubmitDate":"2016-05-26","studyFirstSubmitQcDate":"2016-06-07","studyFirstPostDateStruct":{"date":"2016-06-13","type":"ESTIMATED"},"resultsFirstSubmitDate":"2021-05-18","resultsFirstSubmitQcDate":"2021-08-02","resultsFirstPostDateStruct":{"date":"2021-08-24","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-08-02","lastUpdatePostDateStruct":{"date":"2021-08-24","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR_INVESTIGATOR","investigatorFullName":"Dae Chul Suh","investigatorTitle":"Professor","investigatorAffiliation":"Asan Medical Center"},"leadSponsor":{"name":"Dae Chul Suh","class":"OTHER"},"collaborators":[{"name":"Korea Ginseng Corporation","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study is a 12-month, double-blind, randomized, placebo-controlled trial. The purpose of this study is to determine whether ginseng is effective in the prevention of atherosclerosis and subsequent ischemic stroke. High-risk patients with severe atherosclerosis in the major intracranial arteries and extracranial carotid artery were enrolled."},"conditionsModule":{"conditions":["Ischemic Stroke","Atherosclerosis"],"keywords":["Ginseng","Stroke","Quantitative magnetic resonance flow analysis"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":58,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Ginseng","type":"EXPERIMENTAL","interventionNames":["Dietary Supplement: Ginseng"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Dietary Supplement: Placebo"]}],"interventions":[{"type":"DIETARY_SUPPLEMENT","name":"Ginseng","description":"Korean Red Ginseng extract tablet (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months.","armGroupLabels":["Ginseng"]},{"type":"DIETARY_SUPPLEMENT","name":"Placebo","description":"Placebo (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months.","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"The Composite of Cerebral Ischemic Stroke and Transient Ischemic Attack","description":"The 1-year composite of cerebral ischemic stroke and transient ischemic attack downstream to an atherosclerotic lesion","timeFrame":"Twelve months after randomization."},{"measure":"Modified Rankin Scale","description":"Presence of other cerebro-cardiovascular morbidity or mortality assessed by aggravation of patient status (modified Rankin Scale). The modified Rankin Scale is ranging from 0 to 5. The higher scale indicates the worse outcome.","timeFrame":"Twelve months after randomization."}],"secondaryOutcomes":[{"measure":"The Changes in Volumetric Blood Flow (ml/Sec) in Intracranial Vessels.","description":"The changes in volumetric blood flow (ml/sec) in intracranial vessels assessed by quantitative magnetic resonance angiography with noninvasive optimal vessel analysis.","timeFrame":"At randomization and twelve months after randomization."},{"measure":"The Changes of White Matter Hyperintensities.","description":"The changes of white matter hyperintensities, assessed by the Fazekas scale using brain magnetic resonance imaging. The Fazekas scale is a 4 point white matter disease severity scale with values ranging from 0 to 3. It quantifies the amount of white matter T2 hyperintense lesions each in periventricular white matter and deep white matter. Higher scales mean a worse white matter status. In the region of the periventricular white matter, 0 means absence of the lesion; 1, caps or pencil-thin lining lesion; 2, smooth halo lesion; 3, irregular high intense signal extending into the deep shite matter. In the region of the deep white matter, 0 means absence of the lesion; 1, punctate foci lesions; 2, beginning confluence; 3, large confluent hyperintense areas.","timeFrame":"At randomization and twelve months after randomization."},{"measure":"Number of Participants With Changes of Parenchymal Ischemic Lesions","description":"The changes of ischemic parenchymal lesions, assessed by brain magnetic resonance images acquired at randomization and twelve months after randomization. We counted the number of participants who had new ischemic parenchymal lesions at twelve months after randomization.","timeFrame":"At randomization and twelve months after randomization."}],"otherOutcomes":[{"measure":"Drug Compliance","description":"We calculated average drug compliance based on the number of remained drugs at each follow-up.","timeFrame":"At twelve months after randomization."}]},"eligibilityModule":{"eligibilityCriteria":"\"Inclusion Criteria\"\n\nPatients were included if they\n\n1. were aged 20 to 80 years;\n2. had occlusion or severe stenosis (â‰¥ 70%) of extracranial carotid artery and major intracranial arteries (intracranial carotid artery, middle cerebral artery, anterior cerebral artery, intracranial vertebral, basilar, or posterior cerebral artery) as documented by cerebral catheter angiography;\n3. had any risk factor for stroke, such as hypertension, diabetes mellitus, hypercholesterolemia, smoking, alcohol drinking, or previous stroke history;\n4. had no adverse reactions to administration of ginseng; and\n5. agreed to participate in the trial.\n\n\"Exclusion Criteria\"\n\nPatients were excluded if they\n\n1. did not agree to participate in the trial;\n2. had any genetic cerebrovascular diseases;\n3. had adverse reactions to contrast medium;\n4. were pregnant or planning to be pregnant;\n5. had a history of cardioembolic stroke;\n6. had an emboligenic cardiac disease such as atrial fibrillation, valve disease, congestive heart failure, or recent myocardial infarction;\n7. had a risk of stroke of other determined etiology according to the TOAST classification;\n8. had undergone any neurointervention procedure or surgery, such as intra-arterial thrombolysis, angioplasty procedures, carotid endarterectomy, or bypass surgery;\n9. had chronic kidney disease (GFR \\< 30 ml/min); or\n10. had severe hepatic dysfunction.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Dae Chul Suh","affiliation":"Asan Medical Center","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Asan Medical Center","city":"Seoul","zip":"05505","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}}]},"referencesModule":{"references":[{"pmid":"29854792","type":"BACKGROUND","citation":"Zheng M, Xin Y, Li Y, Xu F, Xi X, Guo H, Cui X, Cao H, Zhang X, Han C. Ginsenosides: A Potential Neuroprotective Agent. Biomed Res Int. 2018 May 8;2018:8174345. doi: 10.1155/2018/8174345. eCollection 2018."},{"pmid":"24462216","type":"BACKGROUND","citation":"Zhou Y, Li HQ, Lu L, Fu DL, Liu AJ, Li JH, Zheng GQ. Ginsenoside Rg1 provides neuroprotection against blood brain barrier disruption and neurological injury in a rat model of cerebral ischemia/reperfusion through downregulation of aquaporin 4 expression. Phytomedicine. 2014 Jun 15;21(7):998-1003. doi: 10.1016/j.phymed.2013.12.005. Epub 2014 Jan 22."},{"pmid":"26384017","type":"BACKGROUND","citation":"Bao C, Wang Y, Min H, Zhang M, Du X, Han R, Liu X. Combination of ginsenoside Rg1 and bone marrow mesenchymal stem cell transplantation in the treatment of cerebral ischemia reperfusion injury in rats. Cell Physiol Biochem. 2015;37(3):901-10. doi: 10.1159/000430217. Epub 2015 Sep 18."},{"pmid":"23811400","type":"BACKGROUND","citation":"Aleshin S, Strokin M, Sergeeva M, Reiser G. Peroxisome proliferator-activated receptor (PPAR)beta/delta, a possible nexus of PPARalpha- and PPARgamma-dependent molecular pathways in neurodegenerative diseases: Review and novel hypotheses. Neurochem Int. 2013 Oct;63(4):322-30. doi: 10.1016/j.neuint.2013.06.012. Epub 2013 Jun 25."},{"pmid":"26886418","type":"BACKGROUND","citation":"Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, Brass LM, Schwartz GG, Adams HP Jr, Berger L, Carolei A, Clark W, Coull B, Ford GA, Kleindorfer D, O'Leary JR, Parsons MW, Ringleb P, Sen S, Spence JD, Tanne D, Wang D, Winder TR; IRIS Trial Investigators. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med. 2016 Apr 7;374(14):1321-31. doi: 10.1056/NEJMoa1506930. Epub 2016 Feb 17."},{"pmid":"26045754","type":"BACKGROUND","citation":"Yang Y, Li X, Zhang L, Liu L, Jing G, Cai H. Ginsenoside Rg1 suppressed inflammation and neuron apoptosis by activating PPARgamma/HO-1 in hippocampus in rat model of cerebral ischemia-reperfusion injury. Int J Clin Exp Pathol. 2015 Mar 1;8(3):2484-94. eCollection 2015."},{"pmid":"25832422","type":"BACKGROUND","citation":"Liu XY, Zhou XY, Hou JC, Zhu H, Wang Z, Liu JX, Zheng YQ. Ginsenoside Rd promotes neurogenesis in rat brain after transient focal cerebral ischemia via activation of PI3K/Akt pathway. Acta Pharmacol Sin. 2015 Apr;36(4):421-8. doi: 10.1038/aps.2014.156. Epub 2015 Mar 16."},{"pmid":"18464084","type":"BACKGROUND","citation":"Chen LM, Zhou XM, Cao YL, Hu WX. Neuroprotection of ginsenoside Re in cerebral ischemia-reperfusion injury in rats. J Asian Nat Prod Res. 2008 May-Jun;10(5-6):439-45. doi: 10.1080/10286020801892292."},{"pmid":"22925661","type":"BACKGROUND","citation":"He B, Chen P, Yang J, Yun Y, Zhang X, Yang R, Shen Z. Neuroprotective effect of 20(R)-ginsenoside Rg(3) against transient focal cerebral ischemia in rats. Neurosci Lett. 2012 Sep 27;526(2):106-11. doi: 10.1016/j.neulet.2012.08.022. Epub 2012 Aug 19."},{"pmid":"28592775","type":"BACKGROUND","citation":"Hong KS. Blood Pressure Management for Stroke Prevention and in Acute Stroke. J Stroke. 2017 May;19(2):152-165. doi: 10.5853/jos.2017.00164. Epub 2017 May 31."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"Patients in a single center, from June 2016 to June 2017.","groups":[{"id":"FG000","title":"Ginseng","description":"Korean Red Ginseng extract tablet (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months."},{"id":"FG001","title":"Placebo","description":"Placebo (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"29"},{"groupId":"FG001","numSubjects":"29"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"28"},{"groupId":"FG001","numSubjects":"24"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"5"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Noncompliance","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Ginseng","description":"Korean Red Ginseng extract tablet (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months."},{"id":"BG001","title":"Placebo","description":"Placebo (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"52"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"52"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"63.4","spread":"12.5"},{"groupId":"BG001","value":"58.8","spread":"13.6"},{"groupId":"BG002","value":"60.3","spread":"13.0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"52"}]}],"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"21"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"31"}]}]}]},{"title":"Race and Ethnicity Not Collected","populationDescription":"Race and Ethnicity were not collected from any participant.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"BG002","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"South Korea","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"52"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"52"}]}]}]},{"title":"Hypertension","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"52"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"34"}]}]}]},{"title":"Diabetes mellitus","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"52"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"14"}]}]}]},{"title":"Hyperlipidemia","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"52"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"38"}]}]}]},{"title":"Previous stroke history","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"52"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"22"}]}]}]},{"title":"Atrial fibrillation","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"52"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Myocardial infarction","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"52"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Angina pectoris","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"52"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"7"}]}]}]},{"title":"Alcohol drinking","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"52"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"15"}]}]}]},{"title":"Smoking","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"52"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"18"}]}]}]},{"title":"Antiplatelet medication","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"52"}]}],"categories":[{"title":"Mono antiplatelet","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"17"}]},{"title":"Dual antiplatelet","measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"31"}]},{"title":"Other antiplatelet","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}]},{"title":"None","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"Antihypertensive medication","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"52"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"34"}]}]}]},{"title":"Antidiabetic medication","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"52"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"12"}]}]}]},{"title":"Antihyperlipidemic medication","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"52"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"46"}]}]}]},{"title":"Baseline modified Rankin Scale (mRS)","description":"The modified Rankin scale (mRS) is a 6 point disability scale with possible scales ranging from 0 to 5. If the patient has no stroke symptoms, the value of the mRS is 0; able to carry out all pre-stroke activities, 1; unable to carry out all pre-stroke activities but is able to look after self without daily help, 2; requires some external help but is able to walk without the assistance of another individual, 3; unable to walk or attend to bodily functions without the assistance of another individual, 4; bedridden, incontinent, requires continuous care, 5.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"52"}]}],"categories":[{"title":"mRS 0","measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"43"}]},{"title":"mRS 1","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"6"}]},{"title":"mRS 2","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"mRS 3","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}]},{"title":"mRS 4","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"mRS 5","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"The Composite of Cerebral Ischemic Stroke and Transient Ischemic Attack","description":"The 1-year composite of cerebral ischemic stroke and transient ischemic attack downstream to an atherosclerotic lesion","populationDescription":"Full analysis set","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Twelve months after randomization.","groups":[{"id":"OG000","title":"Ginseng","description":"Korean Red Ginseng extract tablet (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months."},{"id":"OG001","title":"Placebo","description":"Placebo (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"24"}]}],"classes":[{"title":"Ischemic stroke","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Transient ischemic attack","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The null hypothesis is that there is no relationship between ginseng administration and cerebral ischemic events including ischemic stroke and transient ischemic attack. The number of participants who suffered ischemic stroke and the number of paticipants who suffered transient ischemic attack were analyzed together to test the null hypothesis in two by two table.","nonInferiorityType":"OTHER","nonInferiorityComment":"Equality test","pValue":"0.462","statisticalMethod":"Fisher Exact"}]},{"type":"PRIMARY","title":"Modified Rankin Scale","description":"Presence of other cerebro-cardiovascular morbidity or mortality assessed by aggravation of patient status (modified Rankin Scale). The modified Rankin Scale is ranging from 0 to 5. The higher scale indicates the worse outcome.","populationDescription":"Full analysis set","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Twelve months after randomization.","groups":[{"id":"OG000","title":"Ginseng","description":"Korean Red Ginseng extract tablet (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months."},{"id":"OG001","title":"Placebo","description":"Placebo (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"24"}]}],"classes":[{"title":"mRS 0","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"22"}]}]},{"title":"mRS 1","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"}]}]},{"title":"mRS 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"mRS 3","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"mRS 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"mRS 5","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The null hypothesis is that there is no relationship between ginseng administration and modified Rankin Scale at follow-up.","nonInferiorityType":"OTHER","nonInferiorityComment":"Equality test","pValue":"0.34","statisticalMethod":"Fisher Exact"}]},{"type":"SECONDARY","title":"The Changes in Volumetric Blood Flow (ml/Sec) in Intracranial Vessels.","description":"The changes in volumetric blood flow (ml/sec) in intracranial vessels assessed by quantitative magnetic resonance angiography with noninvasive optimal vessel analysis.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At randomization and twelve months after randomization.","groups":[{"id":"OG000","title":"Ginseng","description":"Ginseng: Korean Red Ginseng extract tablet (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months."},{"id":"OG001","title":"Placebo","description":"Placebo: Placebo (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"24"}]}],"classes":[{"title":"The flow change in steno-occlusive lesion","categories":[{"title":"Improved","measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"}]},{"title":"No change","measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"18"}]},{"title":"Aggravated","measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"1"}]}]},{"title":"The flow change in collateral vessel","categories":[{"title":"Improved","measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"}]},{"title":"No change","measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"9"}]},{"title":"Aggravated","measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The null hypothesis is that there is no relationship between ginseng administration and flow change in steno-occlusive lesion.","nonInferiorityType":"OTHER","nonInferiorityComment":"Equality test","pValue":"0.13","statisticalMethod":"Fisher Exact"},{"groupIds":["OG000","OG001"],"groupDescription":"The null hypothesis is that there is no relationship between ginseng administration and flow change in collateral vessel.","nonInferiorityType":"OTHER","nonInferiorityComment":"Equality test","pValue":"0.17","statisticalMethod":"Chi-squared"}]},{"type":"SECONDARY","title":"The Changes of White Matter Hyperintensities.","description":"The changes of white matter hyperintensities, assessed by the Fazekas scale using brain magnetic resonance imaging. The Fazekas scale is a 4 point white matter disease severity scale with values ranging from 0 to 3. It quantifies the amount of white matter T2 hyperintense lesions each in periventricular white matter and deep white matter. Higher scales mean a worse white matter status. In the region of the periventricular white matter, 0 means absence of the lesion; 1, caps or pencil-thin lining lesion; 2, smooth halo lesion; 3, irregular high intense signal extending into the deep shite matter. In the region of the deep white matter, 0 means absence of the lesion; 1, punctate foci lesions; 2, beginning confluence; 3, large confluent hyperintense areas.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At randomization and twelve months after randomization.","groups":[{"id":"OG000","title":"Ginseng","description":"Korean Red Ginseng extract tablet (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months."},{"id":"OG001","title":"Placebo","description":"Placebo (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"24"}]}],"classes":[{"title":"Periventricular white matter","categories":[{"title":"Fazekas scale 0","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]},{"title":"Fazekas scale 1","measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"}]},{"title":"Fazekas scale 2","measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"10"}]},{"title":"Fazekas scale 3","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]},{"title":"Deep white matter","categories":[{"title":"Fazekas scale 0","measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"6"}]},{"title":"Fazekas scale 1","measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"15"}]},{"title":"Fazekas scale 2","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]},{"title":"Fazekas scale 3","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The null hypothesis is that there is no relationship between ginseng administration and periventricular white matter lesions at follow-up.","nonInferiorityType":"OTHER","nonInferiorityComment":"Equality test","pValue":"0.74","statisticalMethod":"Fisher Exact"},{"groupIds":["OG000","OG001"],"groupDescription":"The null hypothesis is that there is no relationship between ginseng administration and deep white matter lesions at follow-up.","nonInferiorityType":"OTHER","nonInferiorityComment":"Equality test","pValue":"0.95","statisticalMethod":"Fisher Exact"}]},{"type":"SECONDARY","title":"Number of Participants With Changes of Parenchymal Ischemic Lesions","description":"The changes of ischemic parenchymal lesions, assessed by brain magnetic resonance images acquired at randomization and twelve months after randomization. We counted the number of participants who had new ischemic parenchymal lesions at twelve months after randomization.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At randomization and twelve months after randomization.","groups":[{"id":"OG000","title":"Ginseng","description":"Korean Red Ginseng extract tablet (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months."},{"id":"OG001","title":"Placebo","description":"Placebo (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"24"}]}],"classes":[{"categories":[{"title":"Ischemic lesion (+)","measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"15"}]},{"title":"Ischemic lesion (-)","measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The null hypothesis is that there is no relationship between ginseng administration and parenchymal ischemic lesions at follow-up.","nonInferiorityType":"OTHER","nonInferiorityComment":"Equality test","pValue":"0.23","statisticalMethod":"Chi-squared"}]},{"type":"OTHER_PRE_SPECIFIED","title":"Drug Compliance","description":"We calculated average drug compliance based on the number of remained drugs at each follow-up.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percentage of drug compliance","timeFrame":"At twelve months after randomization.","groups":[{"id":"OG000","title":"Ginseng","description":"Korean Red Ginseng extract tablet (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months."},{"id":"OG001","title":"Placebo","description":"Placebo (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"24"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.4","spread":"4.7"},{"groupId":"OG001","value":"97.8","spread":"4.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The null hypothesis is that there is no relationship between ginseng administration and drug compliance at follow-up.","nonInferiorityType":"OTHER","nonInferiorityComment":"Equality test","pValue":"0.79","statisticalMethod":"Wilcoxon (Mann-Whitney)"}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"1, 3, 6 and 12 months after randomization.","eventGroups":[{"id":"EG000","title":"Ginseng","description":"Korean Red Ginseng extract tablet (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months.","deathsNumAffected":0,"deathsNumAtRisk":29,"seriousNumAffected":0,"seriousNumAtRisk":29,"otherNumAffected":1,"otherNumAtRisk":29},{"id":"EG001","title":"Placebo","description":"Placebo (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months.","deathsNumAffected":1,"deathsNumAtRisk":29,"seriousNumAffected":1,"seriousNumAtRisk":29,"otherNumAffected":2,"otherNumAtRisk":29}],"seriousEvents":[{"term":"Death","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":29}]}],"otherEvents":[{"term":"Constipation","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Bruise","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":29},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Subjective hair loss","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":29}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"1. The difficulty in determining the size of the study population due to the lack of previous studies.\n2. The relatively short follow-up period considering chronic atherosclerotic disease.\n3. The absence of surrogate biochemical markers to confirm ginsenosides' effects."},"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Dr. Dae Chul Suh","organization":"Asan Medical Center","email":"dcsuh@amc.seoul.kr","phone":"+82-2-3010-4366"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2018-03-02","uploadDate":"2020-10-18T04:12","filename":"Prot_SAP_000.pdf","size":205101}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000050197","term":"Atherosclerosis"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000001161","term":"Arteriosclerosis"},{"id":"D000001157","term":"Arterial Occlusive Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M25878","name":"Atherosclerosis","asFound":"Atherosclerosis","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M4159","name":"Arteriosclerosis","relevance":"LOW"},{"id":"M4155","name":"Arterial Occlusive Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"T168","name":"Ginseng","asFound":"Obinutuzumab","relevance":"HIGH"}],"browseBranches":[{"abbrev":"HB","name":"Herbal and Botanical"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":true}